Curculigoside Inhibits the Progression of Osteoarthritis via Regulating Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3

This study aimed to explore the potential effects of curculigoside on NLRP3 expression and catabolic genes in osteoarthritis (OA) development. OA mouse models were generated by destabilizing the medial meniscus (DMM) and treated with curculigoside. Curculigoside treatment resulted in dose-dependent reductions in OARSI scores, with the 20 mu g dose restoring scores to normal levels. Curculigoside increased mRNA and protein levels of iNOS and MMP9 induced by DMM surgery in a dose-dependent manner. Moreover, curculigoside downregulated the expression of NLRP3, NF-KB, and PKR at both mRNA and protein levels. Additionally, curculigoside reversed the effects of IL-1/3 on MMP-9, iNOS, and Col2A mRNA and protein levels in a IP:dose-dependent 203.8.109.20manner, On: similarTue,to 10the Oct NLRP32023 inhibitor12:14:42MCC950. In vivo and in vitro results supported curculigoside's potential to aid cartilage restortion in OA patientby blocking the NLRP3 pathway. These Copyright: American Scientif c Publis he s findings suggest curculigoside as a potential therapeutic option for OA, offering hope for improved public health outcomes Delivered by Inge ta related to this degenerative joint condition.

Automated summary

This study found that curculigoside has the potential to aid cartilage restoration in osteoarthritis patients by inhibiting the NLRP3 pathway.